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Abstract 
 
Ischemia-reperfusion injuries produce reactive oxygen species that promote the 
peroxide lipid oxidation process resulting in the production of an endogenic lipid 
peroxide, 4-hydroxy-trans-2-nonenal (4-HNE), a highly cytotoxic aldehyde that induces 
cell death. We synthesized a novel 4-HNE scavenger – a carnosine-hydrazide derivative, 
L-carnosine hydrazide (CNN) – and examined its neuroprotective effect in a model of 
transient ischemia.  
PC-12 cells were pre-incubated with various doses (0-50 mmol/L) of CNN for 30 min, 
followed by incubation with 4-HNE (250 µM). An MTT assay was performed 24 h later 
to examine cell survival. Transient ischemia was induced by bilateral common carotid 
artery occlusion (BCCO) in the Mongolian gerbil. Animals were assigned to 
sham-operated (n = 6), placebo-treated (n = 12), CNN pre-treated (20 mg/kg; n = 12), 
CNN post-treated (100 mg/kg; n = 11), and histidyl hydrazide (a previously known 
4-HNE scavenger) post-treated (100 mg/kg; n = 7) groups. Heat shock protein 70 
immunoreactivity in the hippocampal CA1 region was evaluated 24 h later, while 
delayed neuronal death using 4-HNE staining was evaluated 7 days later. 
Pre-incubation with 30 mmol/L CNN completely inhibited 4-HNE-induced cell toxicity. 





and by >40% in the post-treated group (p < 0.01). Histidyl hydrazide post-treatment 
elicited no protective effect. CNN pre-treatment resulted in high heat shock protein 70 
and low 4-HNE immunoreactivity in CA1 pyramidal neurons. Higher 4-HNE 
immunoreactivity was also found in the placebo-treated animals than in the CNN 
pre-treated animals. 
Our novel compound, CNN, elicited highly effective 4-HNE scavenging activity in vitro. 
Furthermore, CNN administration both pre- and post-BCCO remarkably reduced 
delayed neuronal death in the hippocampal CA1 region via its induction of heat shock 
protein 70 and scavenging of 4-HNE. 
Keywords: carnosine hydrazide, free radical scavenger, global cerebral ischemia, 









The purpose of neuroprotective therapy during the acute stages of cerebral ischemia is 
to block cytotoxic processes and protect neurons against toxic molecules to prevent cell 
death. Reactive carbonyl species (RCS) are cytotoxic substances generated from 
oxidative stress, including membrane lipid-peroxidation reactions, caused by 
ischemia/reperfusion injuries in the brain [1]. RCS cause damage to proteins, nucleic 
acids, and lipids, the chemical modification of which results in cytotoxicity and 
mutagenicity. In addition to its direct toxic effects, the modification of biomolecules by 
RCS gives rise to a multitude of adducts and cross-linked proteins that have 
increasingly been implicated in aging and the pathology of a wide range of human 
diseases [2,3]. RCS can be classified into three groups: (1) α, β-unsaturated aldehydes, 
such as 4-hydroxy-trans-2-nonenal (4-HNE) and acrolein; (2) keto-aldehydes, such as 
methylglyoxal; and (3) dialdehydes, such as glyoxal and malondialdehyde [4]. Among 
these RCS, 4-HNE represents one of the most abundant and highly cytotoxic aldehydes 
generated during lipid peroxidation. For example, it has been reported that 4-HNE 
greatly contributes to the delayed neuronal death (DND) of pyramidal cells in the CA1 
region of the hippocampus after transient cerebral ischemia [5-7]. Although the cell 





stroke in the hippocampal CA1 region and ultimately induces DNA fragmentation via 
apoptotic processes [8-12]. Although this phenomenon is clearly different from necrosis 
(real infarction; core of infarction) caused by severe ischemia, similar processes can be 
visualized in brain areas surrounding the necrotic tissue. Thus, various types of 
4-HNE-scavenging substances have been examined in attempts to prevent DND.  
L-Carnosine (L-CAR, Fig. 1), a natural β-alanyl-L-histidine dipeptide that is widely 
distributed in skeletal muscle and the central nervous system, was first isolated from 
skeletal muscle extracts by Gulewitsch et al. at the end of the 19th century [13,14]. In 
biological tissues, L-CAR acts as an antioxidant and scavenger of RCS; as such, L-CAR 
may protect tissue from oxidative damage [15,16]. It has been proposed that since 
L-CAR acts as a natural scavenger of cytotoxic aldehydes, it could be a potent and 
selective scavenger of the toxic lipid peroxidation product, 4-HNE [17,19]. In contrast, 
several papers have reported that the histidine analogue, L-histidyl hydrazide 
(histidyl-NHNH2, HH, Fig. 1), is more efficient than L-CAR in 4-HNE scavenging and 
in reducing brain damage [20,21]. The formation of cyclic adduct, L-CAR-4-HNE and 
HH-4-HNE, is presumed (Fig.1). In this study, we integrated the functional groups of 
L-CAR and HH (i.e., amino and imidazole groups and hydrazide and imidazole groups, 





CNN), expecting the formation of a tighter bicyclic adduct (Fig. 1). We also designed 
acetyl derivatives ACNN, CNNA, and ACNNA to investigate the role of the amino and 
the hydrazide groups of CNN (Fig. 1). 
Fig. 1: Structures of L-carnosine (L-Car), L-histidine (L-His), histidyl-NHNH2 (HH), 
L-carnosine hydrazide (CNN), and the acetylamino derivatives, Ac-carnosine-NHNH2 
(ACNN); acetylhydrazide derivative, carnosine-NHNH-Ac (CNNA); 
acetylamino-acetylhydrazide derivative, Ac-carnosine-NHNH-Ac (ACNNA); 






2. Results and discussion 
2.1. Chemistry 
Compounds were prepared as shown in Scheme 1 and 2. L-carnosine was esterified, 
acetylated and treated with hydrazine hydrate to give ACNN (Scheme 1). DCC 
condensation of Cbz-β-Ala and His-OMe afforded Cbz-carnosine-Ome which was 
treated with hydrazine hydrate to give Cbz-carnosine-NHNH2 (Scheme 2). Removal of 
Cbz group of Cbz-carnosine-NHNH2 gave CNN that was further acetylated to give 
diacetylated ACNNA. Acetylation of Cbz-carnosine-NHNH2 followed by 
hydrogenolysis gave monoacetylated CNNA. Detail of the synthesis is given in 
Supplementary Material. 
 
Scheme 1. Synthesis of ACNN. 
a) SOCl2, MeOH, 0 °C 10 min then reflux 1 h, b) Ac2O, MeOH, KHCO3, 0 °C 30 min 
then rt overnight, c) N2H4･H2O, EtOH, rt overnight. 
 
Scheme 2. Syntheses of CNN, ACNNA, and CNNA. 
a) DCC, CH2Cl2, 0 °C 2 h then rt overnight, b) N2H4･H2O, EtOH, rt overnight, c) H2, 








2.2. Measurement of 4-HNE-quenching activity  
The proportion of 4-HNE-quenching activity was calculated by comparing the 4-HNE 
consumption achieved by each compound with that achieved by CNN (defined as 
100%; Fig. 2A, B). Fig. 2A presents the 4-HNE capturing activity of each compound 
tested after 1 h of incubation. CNN, HH, and carnosine-NHNH-Ac (CNNA) were more 
potent than L-CAR, while Ac-carnosine-NHNH2 (ACNN) was less active than L-CAR, 
and Ac-carnosine-NHNH-Ac (ACNNA) elicited the lowest activity. These findings 
suggest that the introduction of an acetyl group masked the activity of CNN, 
demonstrating the significance of the amino and hydrazide groups. Moreover, the amino 
group may be more important than the hydrazide group since ACNN was less active 
than CNNA, but the masked hydrazide group elicited some activity because CNNA was 
more active than L-CAR. 
Fig. 2B depicts the time course of 4-HNE-quenching activity by CNN, L-CAR, and HH. 
While CNN and HH demonstrated similar 4-HNE-capturing rates 1 h after incubation 





4-HNE captured by CNN, HH, and L-CAR corresponded to approximately 90%, 70%, 
and 20%, respectively. 
 
Fig. 2: Depiction of the 4-hydroxy-trans-2-nonenal (4-HNE)-quenching activity of 
L-carnosine hydrazide (CNN), Ac-carnosine-NHNH2 (ACNN), carnosine-NHNH-Ac 
(CNNA), Ac-carnosine-NHNH-Ac (ACNNA), L-carnosine (L-CAR), L-histidine, and 
histidyl hydrazide (HH). (A) The 4-HNE-capturing activity of all compounds after 1 h 
incubation. (B) Time course measurement of the 4-HNE-quenching activity of CNN, 
L-CAR, and HH.  
 
 
2.3. Cell culture and MTT assay 
Fig. 3 illustrates the protective effect of CNN against 4-HNE in PC-12 cells in vitro. 
Pre-incubated (30 min) CNN did not elicit cell toxicity. Furthermore, CNN was able to 
penetrate cells, and elicit protective effects in a dose-dependent manner. Additionally, 
30 mM CNN elicited a complete protective effect against 250 µM 4-HNE. 
 





cell death  
Cells were treated with various concentrations of L-carnosine hydrazide (CNN) for 30 
min followed by 1 day of 4-hydroxy-trans-2-nonenal (4-HNE) exposure. Results from 
the MTT assays are presented (data from 3-6 different experiments) as means ± standard 
deviations. # p < 0.05 compared to PC-12 cells exposed to 4-HNE without CNN (n = 4); 
## p = 0.052 compared to PC-12 cells exposed to 4-HNE without CNN (n = 4). 
 
 
2.4. Protective effect of CNN against DND 
DND was clearly observed in the CA1 subfield of the hippocampus 7 days after 
ischemia (Fig. 4 and 5). More specifically, the number of viable neurons was 70.3 ± 
4.5 per high-power field (HPF) in the sham-operated group versus 1.4 ± 1.3 per HPF in 
the placebo-treated group, revealing a statistically significant loss of neurons following 
bilateral common carotid artery occlusion (BCCO) (p < 0.05). Significantly more viable 
neurons were observed in the CNN pre-administration group (44.9 ± 17.7 per HPF) than 
in the placebo-treated group (p < 0.05; Fig. 3C and Fig. 4). A neuroprotective effect was 
also observed in the CNN post-administration group (24.9 ± 25.1 neurons/HPF, p < 





group (Fig. 4D and Fig. 5). In contrast, no significant difference was observed between 
the HH post-administration and placebo-treated groups (7.4 ± 15.4 neurons/HPF; Fig. 
4E and Fig. 5). Together, these findings indicated that, while both CNN administration 
groups exhibited statistically significant neuroprotective activity, CNN 
pre-administration tended to be more effective than CNN post-administration. 
Specifically, pre-administration of CNN elicited a >60% protective effect against DND 
versus the 40% observed in the post-administration group. 
 
Fig. 4: Neuroprotective effect of L-carnosine hydrazide on the pyramidal neuron layer 
in the middle CA1 region of the hippocampus 7 days after bilateral common carotid 
artery occlusion  
Sections stained with hematoxylin-eosin from (A) sham-operated, (B) placebo-treated, 
(C) L-carnosine hydrazide (CNN)-treated pre-bilateral common carotid artery occlusion 
(BCCO), (D) CNN-treated post-BCCO, and (E) histidyl hydrazide (HH)-treated 
post-BCCO animals. Magnification 400×, scale bar 20 µm. 
 
Fig. 5: Histogram representing the number of viable CA1 pyramidal neurons 





determined with a Student’s t-test. *** p < 0.001 compared to the sham-operated group; 
### p < 0.001 compared to the placebo-treated group; ## p < 0.01 compared to the 
placebo-treated group. Sham = sham-operated group; placebo = placebo-treated group; 
CNN pre = L-carnosine hydrazide pre-administration group; CNN post = L-carnosine 
hydrazide post-administration group; HH post = histidyl hydrazide post-administration 
group. Each value is expressed as mean ± SD. 
 
 
2.5. Evaluation of immunostaining 
Representative photographs of 4-HNE and heat shock protein 70 (Hsp70) 
immunostaining in the hippocampal CA1 region at 24 h after BCCO induction are 
presented in Fig. 6. Higher 4-HNE immunoreactivity was observed in the cytoplasm of 
pyramidal neurons in the placebo-treated group than in the CNN pre-administration 
group. In contrast, the CNN pre-administration group exhibited higher concentrations of 
Hsp70 immunoreactivity in the cell cytoplasm of pyramidal neurons than did the 
placebo-treated group.  
 





70 immunostaining of the pyramidal neuron layer in the middle CA1 region of the 
hippocampus 24 h after bilateral common carotid artery occlusion  
Higher 4-hydroxy-trans-2-nonenal (4-HNE) immunoreactivity was observed in the 
cytoplasm of pyramidal neurons in tissue from a placebo-treated animal than in that 
from an animal that received L-carnosine hydrazide (CNN) prior to bilateral common 
carotid artery occlusion (BCCO) (arrow head). CNN pre-administration resulted in 
higher heat shock protein 70 (Hsp70) immunoreactivity than did placebo treatment. 
Sections were stained with anti-4-HNE antibody and anti-Hsp70 antibody. 




Our study demonstrated that the novel derivative, CNN, had significant neuroprotective 
effects against DND (by scavenging 4-HNE and preserving Hsp70 induction) in the 
hippocampal CA1 region of Mongolian gerbils following temporary bilateral occlusion 
of the common carotid artery.  
We synthesized three new derivatives of CNN, namely ACNN, CNNA, and ACNNA 





superiority of CNN was due to the the reactivity of the amino and hydrazide groups to 
form a covalent bond with 4-HNE. We found that CNN was more potent than the 
previously well-known scavengers, HH, L-histidine, and L-CAR (Fig. 2) [17-23].  
The efficacy of HH in protecting neurons against 4-HNE toxicity has been demonstrated 
in several papers. For example, Guiotto et al. reported that the histidine analogue, HH, 
is more efficient than carnosine in eliciting aldehyde-sequestering effects and in 
protecting SH-SY5Y neuroblastoma cells and rat hippocampal neurons from 
4-HNE-mediated death [21]. Tang et al. also reported HH as being effective in reducing 
brain damage and improving functional outcome in a mouse model of focal ischemic 
stroke [20]. In the current study, we found that the 4-HNE-quenching activities of CNN 
and HH were similar after 60 min of incubation (Fig. 2A). However, after only 20 min 
of incubation, the activity of CNN was remarkably higher than that of HH (e.g. 80% of 
CNN vs 60% of HH, Fig. 2B). The reason for this disparity likely lies in the fact that 
CNN is able to rapidly and tightly react with 4-HNE to form a bicyclic adduct using its 
three functional groups (i.e., amino, imidazole, and hydrazide), while HH captures 
4-HNE gradually and loosely with only “two hands” (imidazole and hydrazide). This 
difference in reaction rate is important, because RCS are generated rapidly after 





(similar to CNN after 60 min incubation) in vitro, no difference in scavenging activity 
was observed when animals were post-treated with HH in our in vivo study. Together, 
these findings suggest that pre-administration of HH may be effective against DND; 
however, since we aimed to apply our novel CNN derivatives to actual clinical 
conditions (i.e., after the onset of ischemia), we did not evaluate HH prior to the 
induction of BCCO. In contrast, CNN elicited a significant neuroprotective effect 
against DND, even after the onset of ischemia; this result is of great clinical 
significance.  
Alongside our evaluation of 4-HNE-quenching activity, we examined 4-HNE and 
Hsp70 immunostaining to elucidate how CNN prevented DND. Previously, 4-HNE was 
proposed to be an important marker of radical-induced lipid peroxidation during 
cerebral post-ischemic reperfusion injury [17-19,24]. Hsp70 is expressed at low levels 
in the normal brain but is upregulated under conditions of oxidative stress, such as in 
the penumbra during the hyperacute stage of stroke [25,26]. Hsp70 is well known for its 
cytoprotective role against acute ischemic stroke [27,28], and the possibility of a 
correlation between Hsp70 expression and increased tolerance to ischemia has been 
reported [29-32]. In the current study, we found that, compared to placebo treatment, 





might be explained by the well-established “calpain-cathepsin hypothesis” [33-36], 
which states that ischemia induces Ca2+ mobilization and Ca2+-induced calpain 
activation. Calpain plays a major role in lysosomal rupture, and lipid peroxidation after 
ischemic re-perfusion produces 4-HNE that carbonylates Hsp70 at the lysosomal 
membrane. Carbonylation of Hsp70 leads to not only loss of its chaperone function, but 
also vulnerability to calpain cleavage. Lysosomal membrane damage is most remarkable 
when Ca2+-induced calpain activation and 4-HNE-induced Hsp70 carbonylation 
function in parallel. Consequently, the loss of normal (non-carbonylated) Hsp70 results 
in the rupture or permeabilization of lysosomal membranes and cathepsin release. These 
reactions all occur specifically in the CA1 region of the hippocampus and can be the 
trigger of CA1-related neuronal death.  
The limitation of CNN is the relatively high dose 100 to 200 mg/kg in animal 
experiments. This could be overcome by structure modification of CNN to improve the 








This study demonstrated that our newly developed carnosine-hydrazide derivative 
elicited high 4-HNE-scavenging activity, with CNN exhibiting highly effective 
scavenging activity in vitro. CNN administration in Mongolian gerbils also remarkably 
reduced DND in the CA1 region of the hippocampus after transient cerebral ischemia 
induced by temporary BCCO. The highly effective scavenging ability of CNN could be 
due to its ability to prevent 4-HNE-induced Hsp70 carbonylation. As 4-HNE has been 
implicated in many neurodegenerative disorders, these novel derivatives may be 
effective in treating a number of diseases associated with 4-HNE pathogenesis, such as 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and 
cardiovascular diseases such as atherosclerosis and stroke [20,37-41].  We are currently 
developing CNN derivatives to improve the pharmacokinetic property and to extend the 








4.1. General information 
All procedures in this study were carried out in strict accordance with the Welfare and 
Management of Animals Act (Act No. 105 of 1973); standards relating to the Care and 
Keeping and Reducing Pain of Laboratory Animals (Notice of the Ministry of the 
Environment No. 84 of 2013); Fundamental Guidelines for Proper Conduct of Animal 
Experiments and Related Activities in Academic Research Institutions under the 
jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology 
(Notice of the Ministry of Education, Culture, Sports, Science and Technology, No. 71 
of 2006); Guidelines for Proper Conduct of Animal Experiments (Science Council of 
Japan, 2006); Methods of Destruction of Animals (Notice of the Ministry of the 
Environment No. 105 of 2007); and the guidelines for animal experimentation from the 
Animal Research Center of Kurume University. 
All animal experiments were reviewed by the Institutional Animal Care and Use 
Committee and approved by the president of Kurume University (IACUC #2016-172, 
#2017-033). All induction was performed under anesthesia, and all efforts were made to 
minimize suffering. 





NC, USA). A Student’s t-test was applied to compare the number of surviving neurons 
in the CA1 of each of the five groups. Data are presented as mean ± standard deviation 
(SD). A p-value of < 0.05 was considered significant. 
 
4.2. Animals  
Adult male Mongolian gerbils (MON/JmsGbs, Nihon SLC Co., Shizuoka, Japan), 
weighting 60-100 g, were used for all experiments. The gerbils were kept in a controlled 
environment (22 ± 2°C, 55 ± 5% humidity) and both laboratory food and tap water 
were available ad libitum. The colony was maintained on a 12 h light/dark cycle, with 
lights on between 7:00 and 19:00.  
 
4.3. Drugs 
In addition to CNN, we designed three acetyl-masked derivatives to study the role of the 
amino and hydrazide groups, i.e., the acetylamino derivative, ACNN, the 
acetylhydrazide derivative, CNNA, and the acetylamino-acetylhydrazide derivative, 
ACNNA (Fig. 1). These compounds were synthesized as described in Scheme 1, 2, and 
the Supplementary Data Material. The structures of these derivatives were confirmed 






4.4. Measurement of 4-HNE-quenching activity  
In this study, 4-HNE-quenching activity was evaluated by measuring 4-HNE 
consumption. CNN, ACNN, CNNA, ACNNA, L-CAR, L-histidine, or HH (2 mmol/L) 
was incubated with 4-HNE (200 µM) in phosphate-buffered saline (PBS, pH 7.4) at 
37°C. The ability of the compounds to capture 4-HNE was evaluated by measuring 
4-HNE consumption using high-performance liquid chromatography (CAPCELL PAK 
C18 UG80 at 37°C, eluted by acetonitrile/10 mM PBS (pH 7.4) (60/40 (v/v)), flow rate 
0.50 ml/min). Captured 4-HNE (%) was calculated as follows: 
Captured 4-HNE (%) = 100 – [(AT/A0)×100] 
A0: 4-HNE peak area at time 0 
AT: 4-HNE peak area at time T 
 
4.5. Cell culture and MTT assay 
The rat adrenal pheochromocytoma cell line, PC-12, was maintained in RPNI-1640 
(Wako, Osaka, Japan) supplemented with 5% heat-inactivated fetal bovine serum 
(Biosera, Nuaille, France) and 10% heat-inactivated horse serum (ThermoFisher 





24-well plate in 250 µL of the culture medium. After 1 day, various concentrations of 
2.5 µL CNN dimethyl sulfoxide solution were added to the medium for 30 min. The 
culture medium containing CNN was then replaced with fresh, CNN-free medium. 
Finally, 4-HNE ethanol solution (Merck Millipore, Billerica, MA, USA) was added, and 
cells were further incubated for another 1 day before the MTT assay was conducted. 
 
4.6. BCCO 
Transient cerebral ischemia was induced by temporary BCCO in Mongolian gerbils. 
Briefly, animals were anesthetized with 2% isoflurane in a mixture of 30% oxygen and 
70% nitrous oxide. The common carotid arteries were then dissected from their sheaths 
via a ventral midline cervical incision and occluded with ligatures for 5 min. After 
removing the ligatures, the wound was closed. The rectal temperature was maintained 
between 37.5°C and 38.5°C by a self-regulating heat pad during cerebral ischemia. All 
procedures were performed accurately under a microscope.  
Mongolian gerbils were assigned into five groups: (1) sham-operated group (BCCO was 
not induced, n = 6), (2) placebo-treated group (2 ml of distilled water was administered 
intraperitoneally 20 min prior to BCCO, n = 12), (3) CNN pre-administration group (2 





12), (4) CNN post-administration group (2 mL of CNN [100 mg/kg] was 
intraperitoneally administered immediately after BCCO, n = 11), (5) HH 
post-administration group (2 mL of HH [100 mg/kg] was intraperitoneally administered 
immediately after BCCO, n = 7).  
 
4.7. Histopathological evaluation 
In order to determine the rate of DND, Mongolian gerbils were perfused with 4% 
paraformaldehyde in 0.1 M PBS (pH 7.4) following a heparinized saline flash under 
deep anesthesia with isoflurane 7 days after BCCO. The brains were then removed and 
post-fixed in the same fixative overnight at 4°C. Brain tissues were embedded in 
paraffin, and 4 µm-thick, successive coronal sections were prepared using a microtome. 
Brain sections were stained with hematoxylin-eosin, and hippocampal CA1 damage was 
evaluated by counting the number of surviving pyramidal neurons within the middle 
CA1 subfield at high power using a light microscope. Only neurons with visibly normal 
nuclei were counted.  
 
4.8. Immunohistopathological evaluation 





immunoreactivity in the hippocampal CA1 region of placebo-treated and CNN 
pre-administration groups 24 h after the induction of BCCO. Brain sections were 
prepared in the same manner as those for histopathological evaluation. Then, 4-HNE as 
an oxidative stress marker was analyzed using antibodies against 4-HNE 1:100 (abcam, 
Cat. #: ab48506; Cambridge, UK), and Hsp70 as a neuroprotective marker was analyzed 
using antibodies against Hsp70 1:1000 (abcam, Cat. #: ab181606; Cambridge, UK).  
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Chemicals were purchased from Aldrich, Fluka, Kanto Chemical, Nacalai Tesque, Tokyo Chemical 
Industry and Wako. Thin layer chromatography (TLC) was performed on pre-coated plates (Merck 
TLC sheets silica 60 F254 and Fuji silysia chemical Ltd. TLC sheets Chromatorex NH silica). 
Chromatography was carried out on Silica Gel 60 N (40-100 mesh) (Kanto Chemical) and NH silica 
gel Chromatorex (NH, 100-200 mesh) (Fuji silysia chemical Ltd.). Nuclear magnetic resonance 
(NMR) spectra were recorded on a JEOL JNM-AL300 spectrometer. Chemical shifts are referenced 
to a deuterated solvent signal. Infrared (IR) spectra were recorded on a PerkinElmer Frontier by using 
the attenuated total reflection (ATR) method. Mass spectra and high-resolution mass spectra (HRMS) 
were recorded on a JEOL JMS-DX303HF using positive fast atom bombardment (FAB) with 3-
nitrobenzyl alcohol as the matrix. 
 
Synthesis of Ac-carnosine-NHNH2 (ACNN) (Scheme 1) 
 
Carnosine-OMe 2HCl 
Thionyl chloride (0.25 ml, 3.3 mM) was added dropwise to a suspension of L-carnosine (447 mg, 2 
mM) in MeOH (20 ml) at 0°C. The reaction mixture was stirred at 0°C for 10 min, and then refluxed 
for 1 h. After cooling to 22 ± 2°C, the solvent was removed in vacuo. The product was used in the 
next step without further purification. 
 
Ac-Carnosine-OMe 
Acetic anhydride (1 ml, 10 mM) and KHCO3 (1 g, 10 mM) were added to a solution of carnosine-
OMe 2HCl in MeOH (30 ml) at 0°C under nitrogen atmosphere. The reaction mixture was stirred at 
0°C for 30 min, then at 22 ± 2°C overnight. The precipitate was filtered and the solvent was 
evaporated. The residue was treated with acetone, and the insoluble precipitate was removed by 
filtration. After evaporation of the solvent, the residue was purified by flash silica gel column 
chromatography (CH2Cl2:MeOH = 4:1) to yield Ac-Carnosine-OMe as a white solid (178 mg, 63%, 
two steps). 
1H-NMR (300 MHz, CD3OD) δ 7.68 (s, 1H), 6.92 (s, 1H), 4.70 (dd, J = 8.4, 5.4 Hz, 1H), 3.69 (s, 
3H), 3.39 (t, J = 6.8 Hz, 2H), 3.12 (dd, J = 14.8, 5.4 Hz , 1H), 3.01 (dd, J = 14.9, 8.4 Hz, 1H), 2.43 
(t, J = 6.8 Hz, 2H), 1.91 (s, 3H). 13C-NMR (75 MHz, CD3OD) δ 173.8, 173.6, 173.4, 136.5, 134.6, 
118.2, 54.0, 52.8, 36.9, 36.3, 29.9, 22.6. IR (ATR) 3305, 2953, 1758, 1630, 1538, 1427, 1212 cm-1. 
MS (FAB) m/z 283.3 (M+H)+. HRMS (FAB) : Calcd for C12H19N4O4: 283.1406, Found 283.1406 
 
Ac-carnosine-NHNH2 (ACNN) 
Hydrazine monohydrate (1.1 ml, 22 mM) was added to a solution of Ac-Carnosine-OMe (175 mg, 
1.1 mM) in EtOH (10 ml), and the reaction mixture was stirred at 22 ± 2°C overnight. The resulting 
precipitate was filtered, and then washed with EtOH (50 ml) and Et2O (200 ml) to yield Ac-carnosine-
NHNH2 (ACNN) as a white solid (50 mg, 28%). 
1H-NMR (300 MHz, D2O) δ 7.66 (s, 1H), 6.93 (s, 1H), 4.49 (dd, J = 8.0, 6.8 Hz, 1H), 3.33 (t, J = 6.5 
Hz, 2H), 3.02 (dd, J = 14.8, 6.5 Hz, 1H), 2.93 (dd, J = 14.8, 8.4 Hz, 1H), 2.42 (t, J = 6.5 Hz, 2H), 
1.89 (s, 3H). 13C-NMR (75 MHz, D2O) δ 174.7, 174.6, 172.5, 136.7, 133.5, 117.5, 53.2, 36.1, 35.3, 
29.3, 22.2. IR (ATR) 3286, 2922, 1651, 1633, 1623, 1455, 1425 cm-1. MS (FAB) m/z 283.3 (M+H)+. 
HRMS (FAB) : Calcd for C11H19N6O3 : 283.1519, Found 283.1526. 
 
Synthesis of L-carnosine hydrazide (CNN) (Scheme 2) 
 
Cbz-carnosine-OMe 
Dicyclohexylcarbodiimide (500 mg, 2.4 mM) was gradually added to a solution of N-carbobenzoxy-
-β-alanine (450 mg, 2 m M) and L-histidine methyl ester in CH2Cl2 (50 ml) at 0°C. The reaction 
mixture was stirred at 0°C for 2 h, then at 22 ± 2°C overnight. The resulting precipitate was filtered 
and the filtrate was washed with aqueous saturated NaHCO3 (2 x 20 ml). The aqueous layer was 
extracted with CH2Cl2 (2 x 30 ml), and the combined organic layer was dried over Na2SO4. After 
removal of the solvent in vacuo, the residue was purified by silica gel column chromatography 
(AcOEt:MeOH = 5:1) to yield cbz-carnosine-OMe as a white solid (411 mg, 55%). 
1H-NMR (300 MHz, CD3OD) δ 7.56 (d, J = 1.1 Hz, 1H), 7.33 - 7.26 (m, 5H), 6.86 (s, 1H), 5.05 (s, 
2H), 4.68 (dd, J = 8.2, 5.5 Hz, 1H), 3.66 (s , 3H), 3.35 (t, J = 6.8 Hz, 2H), 3.09 (dd, J = 14.9, 5.5 Hz, 
1H), 2.98 (dd, J = 14.8, 8.2 Hz, 1H), 2.42 (t, J = 6.8 Hz, 2H). 13C-NMR (75 MHz, CD3OD) δ 173.9, 
173.6, 158.8, 138.4, 136.5, 134.8, 129.6, 129.1, 128.9, 118.1, 67.4, 54.1, 52.8, 38.3, 36.8, 30.0. IR 
(ATR) 3287, 2952, 1700, 1649, 1251 cm-1. MS (FAB) m/z 375.3 (M+H)+. HRMS (FAB) : Calcd for 
C18H23N4O5 : 375.1668, Found 375.1670. 
 
Cbz-carnosine-NHNH2 
Hydrazine monohydrate (0.55 ml, 11 mM) was added to a solution of cbz-carnosine-OMe (400 mg, 
1.1 mM) in EtOH (30 ml), and the reaction mixture was stirred at 22 ± 2°C overnight. After cooling 
the mixture to 0°C, the resulting precipitate was filtered, and then washed with EtOH (50 ml) and 
Et2O (200 ml) to yield cbz-carnosine-NHNH2 as a white solid (275 mg, 69%). The product was used 
in the next step without further purification. 
1H-NMR (300 MHz, CD3OD) δ 7.56 (d, J = 1.1 Hz, 1H), 7.35 - 7.29 (m, 5H), 6.86 (s, 1H), 5.07 (s, 
2H), 4.55 (dd, J = 8.1, 6.1 Hz, 1H), 3.35 (d, J = 6.9 Hz, 2H), 3.04 (dd, J = 14.5, 5.9 Hz, 1H), 2.90 (dd, 
J = 14.8, 8.2 Hz, 1H), 2.40 (t, J = 6.8 Hz, 2H). 13C-NMR (75 MHz, dimethyl sulfoxide) δ 170.7, 
170.5, 156.3, 137.4, 134.9, 133.9, 128.6, 128.0, 117.4, 65.4, 51.7, 37.1, 35.7, 29.9. IR (ATR) 3288, 
3208, 3032, 2940, 1703, 1660, 1635, 1262 cm-1. MS (FAB) m/z 375.3 (M+H)+. HRMS (FAB) : Calcd 
for C17H23N6O4 : 375.1781, Found 375.1779. 
 
L-carnosine hydrazide (CNN) 
10% Pd/C (75 mg, 20 wt%) was added to a solution of cbz-carnosine-NHNH2 (375 mg, 1 mM) in 
MeOH (50 ml). The reaction flask was flashed five times with hydrogen, and then the reaction mixture 
was stirred at 22 ± 2°C overnight under hydrogen atmosphere. The mixture was filtered through a 
celite pad, and the residue was washed with MeOH (20 ml). After combining the organic layer, the 
solvent was removed under reduced pressure. The residue was purified by NH-silica gel column 
chromatography (AcOEt:MeOH = 2:1) to yield L-carnosine hydrazide (CNN) as a white solid (175 
mg, 73%).  
1H-NMR (300 MHz, CD3OD) δ 7.59 (d, J = 1.2 Hz, 1H), 6.87 (d, J = 0.9 Hz, 1H), 4.60 (dd, J = 8.6, 
5.7 Hz, 1H), 3.08 (ddd, J = 14.7, 5.7, 0.5 Hz, 1H), 2.98 - 2.81 (m, 3H), 2.34 (td, J = 6.5, 2.2 Hz, 2H). 
13C-NMR (75 MHz, CD3OD) δ 174.7, 172.9, 136.5, 134.8, 118.4, 53.6, 39.4, 39.1, 30.5. IR (ATR) 
3350, 3275, 3179, 3023, 2919, 1631, 1561, 1455, 1425 cm-1. MS (FAB) m/z 241.2 (M+H)+. HRMS 
(FAB) : Calcd for C9H17N6O2 : 241.1413, Found 241.1412. 
 
Synthesis of Ac-carnosine-NHNH-Ac (ACNNA) (Scheme 2) 
 
Ac-carnosine-NHNH-Ac (ACNNA) 
Acetic anhydride (1.5 ml, 15 mM) and diisopropylethylamine (2 ml, 10.5 mM) were added to a 
solution of carnosine hydrazide (170 mg, 0.7 mM) in MeOH (30 ml) at 0°C under nitrogen 
atmosphere. The reaction mixture was stirred at 0°C for 30 min, then at 22 ± 2°C overnight. The 
resulting precipitate was filtered and the solvent was evaporated in vacuo. The residue was purified 
by silica gel column chromatography (CH2Cl2:MeOH = 1:1) to yield Ac-carnosine-NHNH-Ac 
(ACNNA) as a white solid (125 mg, 55%). 
1H-NMR (300 MHz, CD3OD) δ 7.59 (d, J = 1.1 Hz, 1H), 6.91 (s, 1H), 4.69 (dd, J = 8.1, 5.5 Hz, 1H), 
3.41 - 3.34 (m, 2H), 3.16 (dd, J = 15.1, 5.1 Hz, 1H), 2.97 (dd, J = 15.1, 8.0 Hz, 1H), 2.39 (td, J = 6.7, 
1.5 Hz, 2H), 2.00 (s, 3H), 1.90 (s, 3H). 13C-NMR (75 MHz, D2O) δ 175.3, 175.2, 174.1, 173.5, 137.3, 
133.8, 118.5, 53.5, 36.8, 36.0, 30.0, 22.9, 20.9. IR (ATR) 3274, 3178, 3027, 2934, 1634, 1603, 1557, 




Synthesis of carnosine-NHNH-Ac (CNNA) (Scheme 2 ) 
 
Cbz-Carnosine-NHNH-Ac 
Acetic anhydride (0.5 ml, 5 mM) and diisopropylethylamine (1.5 ml, 8 mM) were added to a solution 
of Cbz-Carnosine-NHNH2 (375 mg, 1 mM) in MeOH (20 ml) at 0°C. The reaction mixture was stirred 
at 0°C for 30 min, then at 22 ± 2°C overnight. The resulting precipitate was filtered and the solvent 
was evaporated in vacuo. The residue was purified by NH-silica gel column chromatography 
(AcOEt:MeOH = 2:1) to yield cbz-Carnosine-NHNH-Ac as a white solid (330 mg, 79%). 
1H-NMR (300 MHz, CD3OD) δ 7.56 (d, J = 1.0 Hz, 1H), 7.35 - 7.28 (m, 5H), 6.89 (s, 1H), 5.06 (s, 
2H), 4.69 (dd, J = 8.0, 5.5 Hz, 1H), 3.35 (t, J = 5.0 Hz, 2H), 3.15 (dd, J = 15.0, 5.3 Hz, 1H), 2.97 (dd, 
J = 14.9, 8.0 Hz, 1H), 2.40 (t, J = 6.7 Hz, 2H), 1.99 (s, 3H). 13C-NMR (75 MHz, CD3OD) δ 173.9, 
172.7, 172.3, 158.9, 138.4, 136.5, 133.7, 129.6, 129.1, 128.9, 119.4, 67.5, 53.2, 38.3, 37.0, 30.3, 20.4. 
IR (ATR) 3189, 3033, 2901, 1686, 1638, 1602, 1484, 1264, 1230 cm-1. MS (FAB) m/z 417.3 (M+H)+. 
HRMS (FAB) : Calcd for C19H25N6O5 : 417.1886, Found 417.1892. 
 
Carnosine-NHNH-Ac (CNNA) 
10% Pd/C (66 mg, 20 wt%) was added to a solution of cbz-Carnosine-NHNH-Ac (330 mg, 0.8 mM) 
in MeOH (25 ml). The reaction flask was flashed five times with hydrogen, then the reaction mixture 
was stirred at 22 ± 2°C overnight under hydrogen atmosphere. The mixture was filtered through a 
celite pad, and the residue was washed with MeOH (20 ml). After combining the organic layer, the 
solvent was removed under reduced pressure. The residue was purified by NH-silica gel column 
chromatography (AcOEt:MeOH = 2:1) to yield Carnosine-NHNH-Ac (CNNA) as a white solid (180 
mg, 80%).  
1H-NMR (300 MHz, CD3OD) δ 7.58 (d, J = 1.1 Hz, 1H), 6.90 (d, J = 0.9 Hz, 1H), 4.71 (dd, J = 8.3, 
5.2 Hz, 1H), 3.18 (dd, J = 14.7, 5.5 Hz, 1H), 2.98 (dd, J = 15.0, 8.3 Hz, 1H), 2.87 (t, J = 6.4 Hz, 2H), 
2.36 (td, J = 6.4, 3.1 Hz, 2H) , 1.99 (s, 3H). 13C-NMR(75 MHz, CD3OD) δ 174.6, 172.5, 172.0, 136.5, 
133.8, 119.6, 53.3, 39.1, 39.0, 30.3, 20.5. IR (ATR) 3350, 3276, 3181, 3024, 2936, 1632, 1560, 1425, 
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